Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1

Journal of Acquired Immune Deficiency Syndromes

Volumn 37, Issue SUPPL. 1, 2004, Pages 1166-1169

  Patel, Atul ^a   Patel, Ketan ^a   Patel, Jagdish ^b   Shah, Nitesh ^a   Patel, Bhupendra ^c   Rani, Shubha ^d  

^a Sterling Hospital   (India)

^b Adit Diagnostic Center   (India)

^c Shashwat Diagnostic   (India)

^d B V Patel PERD Center   (India)

Author keywords

Efavirenz; Highly active antiretroviral therapy (HAART); HIV tuberculosis (TB) coinfection; Paradoxical worsening; Rifampicin

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; PYRAZINAMIDE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; STREPTOMYCIN; ZIDOVUDINE;

ACID FAST BACTERIUM; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; LIVER TOXICITY; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROLOGICAL COMPLICATION; OBSERVATION; OPPORTUNISTIC INFECTION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; SIDE EFFECT; SLEEP DISORDER; TOXIC HEPATITIS; TREATMENT OUTCOME; TUBERCULOSIS; VOMITING;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INDIA; MALE; MIDDLE AGED; OXAZINES; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 4444347045     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000135956.96166.f0     Document Type: Article

References (25)

1. Dye C, Scheele S, Dolin P, et al. Global burden of TB: estimated incidence, prevalence, and mortality by country. JAMA. 1999;282:677-686.
2. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS. 2002;16:75-83.
3. Badri M, Wilson D, Wood R. Effect of HAART on incidence of TB in South Africa: a cohort study. Lancet. 2002;359:2059-2064.
4. Girardi E, Palmieri F, Cingolani A, et al. Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26:326-331.
5. Spradling P, Drociuk D, McLaughlin S, et al. Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak. Clin Infect Dis. 2002;35:1106-1112.
6. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line anti-TB drugs among patients treated for active TB. Am J Respir Crit Care Med. 2003;167:1472-1477.
7. Jones JL, Hanson DL, Dworkin MS, et al. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis. 2000;4:1026-1031.
8. Pozniak A. Mycobacterial diseases and HIV. J HIV Ther. 2002;7:13-16.
9. Bertz R, Hsu A, Lam W, et al. Pharmacokinetic interaction between lopinavir/ritonavir (ABT-378r) and other non-HIV drugs. AIDS. 2000; 14(suppl 4):S100.
10. Borin MT, Chambers JH, Carel BJ, et al. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther. 1997;61:544-553.
11. Indinavir Pharmacokinetic Study Group. Indinavir (MK 639) drug interaction studies [abstract MoB174]. 11th International Conference on AIDS, Vancouver, British Columbia, Canada, 1996.
12. Kerr BM, Lee C, Yuen G, et al. Overview of in-vitro and in-vivo drug interaction studies of nelfinavir mesylate, a new HIV-1 protease inhibitor [abstract 373]. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1997.
13. Kerr BM, Daniels R, Clendeninn N. Pharmacokinetic interaction of nelfinavir with half dose rifabutin. Canadian Journal of Infectious Diseases. 1999;10(suppl B):21B.
14. Sadler B, Gillotin C, Chittick GE, et al. Pharmacokinetic drug interactions with amprenavir [abstract 12389]. 12th World AIDS Conference, Geneva, 1998.
15. Sahai J, Stewart F, Swick L, et al. Rifabutin reduces saquinavir plasma levels in HIV infected patients [abstract a-27]. 36th International Conference on Antimicrobial Agents and Chemotherapy, 1996.
16. Lopez-Cortes LF, Ruiz R, Viciana P, et al. Pharmacokinetic interactions between rifampin and efavirenz in patients with tuberculosis and HIV infection. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4-8, 2001.
17. Salomon N, Perlmann DC, Friedmann P, et al. Predictors and outcome of multi-drug resistant tuberculosis. Clin Infect Dis. 1995;21:1245-1252.
18. Mannheimer SB, Sepkowitz KA, Stoekle M, et al. Risk factors and outcome of human immunodeficiency virus infected patients with sporadic multidrug resistant tuberculosis in New York City. Int J Tuberc Lung Dis. 1997;1:319-325.
19. Park MM, Davis AL, Schluger NW, et al. Outcome of MDR-TB patients, 1983-93. Prolonged survival with appropriate therapy. Am J Respir Crit Care Med. 1996;153:317-324.
20. Breen RA, Lipman MCI, Johnson MA. Increased incidence of peripheral neuropathy with coadministration of stavudine and isoniazid in HIV infected individuals. AIDS. 2000;14:615.
21. Hung CC, Chen MY, Hsiao CF, et al. Improved outcomes of H1V-1 infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS. 2003;17:2615-2622.
22. Moore RD, Wong WME, Keruly JC, et al. Incidence of neuropathy in HIV infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS. 2000;14:273-278.
23. Cheng VCC, Ho PL, Lee RA, et al. Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients. Eur J Clin Microbiol Infect Dis. 2002;21:803-809.
24. Wende KA, Alwood KS, Gachuhi R, et al. Paradoxical worsening of tuberculosis in HIV-infected persons. Chest. 2001;120:193-197.
25. Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 1998;158:157-161.